FDA Expands Indication for PCSK9 Alirocumab (Praluent)

08:49 EDT 30 Apr 2019 | Medscape

The decision allows the cholesterol-lowering drug to be prescribed to reduce the risk for major cardiovascular events, including myocardial infarction and stroke.
Medscape Medical News

Original Article: FDA Expands Indication for PCSK9 Alirocumab (Praluent)


More From BioPortfolio on "FDA Expands Indication for PCSK9 Alirocumab (Praluent)"

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...